191 related articles for article (PubMed ID: 18813833)
1. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples.
Vukmirovic-Popovic S; Escott NG; Duivenvoorden WC
Oncol Rep; 2008 Oct; 20(4):897-903. PubMed ID: 18813833
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Webber MM; Waghray A; Bello D
Clin Cancer Res; 1995 Oct; 1(10):1089-94. PubMed ID: 9815898
[TBL] [Abstract][Full Text] [Related]
3. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
5. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion.
Ishii K; Otsuka T; Iguchi K; Usui S; Yamamoto H; Sugimura Y; Yoshikawa K; Hayward SW; Hirano K
Cancer Lett; 2004 Apr; 207(1):79-87. PubMed ID: 15050736
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Gallardo-Williams MT; Maronpot RR; Wine RN; Brunssen SH; Chapin RE
Prostate; 2003 Jan; 54(1):44-9. PubMed ID: 12481254
[TBL] [Abstract][Full Text] [Related]
7. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
[TBL] [Abstract][Full Text] [Related]
8. PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.
Cumming AP; Hopmans SN; Vukmirović-Popović S; Duivenvoorden WC
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):286-94. PubMed ID: 21826098
[TBL] [Abstract][Full Text] [Related]
9. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium.
Ornstein DK; Englert C; Gillespie JW; Paweletz CP; Linehan WM; Emmert-Buck MR; Petricoin EF
Clin Cancer Res; 2000 Feb; 6(2):353-6. PubMed ID: 10690510
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
11. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
Wan XS; Xu YA; Ware JH; Kennedy AR
Prostate; 2003 Jul; 56(2):131-41. PubMed ID: 12746838
[TBL] [Abstract][Full Text] [Related]
12. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
15. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K
Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845
[TBL] [Abstract][Full Text] [Related]
16. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
17. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA.
Herwig R; Mitteregger D; Djavan B; Kramer G; Margreiter M; Leers MP; Glodny B; Haider DG; Hörl WH; Marberger M
Eur J Clin Invest; 2008 Jun; 38(6):430-7. PubMed ID: 18489403
[TBL] [Abstract][Full Text] [Related]
18. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters.
Khorramizadeh MR; Aalizadeh N; Pezeshki M; Ghahary A; Zeraati H; Berahmeh A; Safa O; Saadat F
Int J Urol; 2005 Jul; 12(7):637-43. PubMed ID: 16045556
[TBL] [Abstract][Full Text] [Related]
19. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
Tajiri M; Ohyama C; Wada Y
Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
[TBL] [Abstract][Full Text] [Related]
20. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
